Axsome Therapeutics News, Axsome Therapeutics Quote, AXSM Quote

Axsome Therapeutics (NQ:AXSM) Delayed: 67.90 +2.18 (3.32%)

Prev. Close

$65.72

Open

$65.50

52 Wk High

$15.74

52 Wk Low

$5.37

Day High

$68.14

Day Low

$65.50

P/E

N/A

EPS

$0.00

Volume

890,721

Friends, Peers and Foes (?): IMVT, ALNY, LEGN, MRK, ABBV (more...)

Apr 17, 2024 09:00 PM AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Apr 15, 2024 07:00 AM Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Apr 12, 2024 02:30 AM AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Apr 10, 2024 07:00 AM Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Apr 3, 2024 09:00 PM AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Apr 1, 2024 06:47 PM Form 4 Axsome Therapeutics, For: Apr 01 Filed by: Jacobson Mark L.
Apr 1, 2024 06:14 PM Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.
Apr 1, 2024 08:27 AM Form 8-K Axsome Therapeutics, For: Mar 28
Apr 1, 2024 07:02 AM Axsome Therapeutics (AXSM) Initiates ENGAGE Phase 3 Trial of Solriamfetol
Apr 1, 2024 07:00 AM Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Entities mentioned with AXSM